J D Siliciano
Overview
Explore the profile of J D Siliciano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
2963
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hermankova M, Ray S, Ruff C, Ingersoll R, DAquila R, Quinn T, et al.
JAMA
. 2001 Jul;
286(2):196-207.
PMID: 11448283
Context: The continued release of human immunodeficiency virus type 1 (HIV-1) into plasma at very low levels during highly active antiretroviral therapy (HAART) can be detected using specialized techniques, but...
2.
Shen A, Siliciano J, Pierson T, Buck C, Siliciano R
Virology
. 2000 Dec;
278(1):227-33.
PMID: 11112497
The introduction of highly active antiretroviral therapy (HAART) for the treatment of HIV-1 infection has allowed dramatic reductions in plasma virus levels to below the limit of detection in many...
3.
Siliciano J, Siliciano R
J Clin Invest
. 2000 Oct;
106(7):823-5.
PMID: 11018068
No abstract available.
4.
Pierson T, Hoffman T, Blankson J, Finzi D, Chadwick K, Margolick J, et al.
J Virol
. 2000 Aug;
74(17):7824-33.
PMID: 10933689
Latently infected resting CD4(+) T cells provide a long-term reservoir for human immunodeficiency virus type 1 (HIV-1) and are likely to represent the major barrier to virus eradication in patients...
5.
Finzi D, Blankson J, Siliciano J, Margolick J, Chadwick K, Pierson T, et al.
Nat Med
. 1999 May;
5(5):512-7.
PMID: 10229227
Combination therapy for HIV-1 infection can reduce plasma virus to undetectable levels, indicating that prolonged treatment might eradicate the infection. However, HIV-1 can persist in a latent form in resting...
6.
Canman C, Lim D, Cimprich K, Taya Y, Tamai K, Sakaguchi K, et al.
Science
. 1998 Sep;
281(5383):1677-9.
PMID: 9733515
The p53 tumor suppressor protein is activated and phosphorylated on serine-15 in response to various DNA damaging agents. The gene product mutated in ataxia telangiectasia, ATM, acts upstream of p53...
7.
Siliciano J, Canman C, Taya Y, Sakaguchi K, Appella E, Kastan M
Genes Dev
. 1998 Feb;
11(24):3471-81.
PMID: 9407038
Data are presented demonstrating that DNA damage leads to specific post-translational modifications of p53 protein. Using two-dimensional peptide mapping of in vivo radiolabeled p53 tryptic phosphopeptides, recombinant truncated p53 protein,...
8.
Janis E, Siliciano J, Isaac D, Griffin C, Hawkins A, Kozak C, et al.
Genomics
. 1994 Sep;
23(1):269-71.
PMID: 7829087
The protein-tyrosine kinase gene Itk is expressed preferentially in T lymphoid cells of the mouse and is induced by IL-2. A related gene, Btk, is expressed in the murine B...
9.
10.
Siliciano J, Morrow T, Desiderio S
Proc Natl Acad Sci U S A
. 1992 Dec;
89(23):11194-8.
PMID: 1280821
T lymphocytes are activated by interactions with antigens, lymphokines, and cell adhesion molecules. Tyrosine phosphorylation has been implicated as important in signaling through each of these pathways, but except for...